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Thoracic surgeons are often involved in the care of patients
with lymphangioleiomyomatosis. These patients may have
spontaneous pneumothorax or chylothorax or may require
evaluation of interstitial lung disease. Because of the rarity of
this disease, the diagnosis of lymphangioleiomyomatosis
may not always be considered by referring clinicians. Proper
diagnosis may lead to significant alterations in patient man-
agement, and it is therefore important for thoracic surgeons to
be familiar with this rare disease. We recently established a
previously missed diagnosis of lymphangioleiomyomatosis
in a 59-year-old woman who had a spontaneous chylothorax.
Case report. The patient is a 59-year-old nonsmoking
woman who had undergone hysterectomy and oophorectomy
for uterine fibroid tumors at the age of 45 years and had since
been receiving estrogen supplements. Six years before pre-
sentation to us she was admitted to an outside hospital with
shortness of breath attributed to a significant left pleural effu-
sion. The fluid was drained and reported to be chylous. A
computed tomogram (CT) of the chest did not show any
parenchymal abnormalities. The effusion did not recur, and
further work-up was not pursued. In the interim, the patient
had progressive dyspnea and was told she had emphysema.
Pulmonary function tests showed severe obstruction unre-
sponsive to bronchodilators, with normal lung volumes and a
diffusion impairment.
The patient became more symptomatic over the 3 weeks
before admission to our thoracic surgery service. Chest x-ray
films demonstrated a significant right pleural effusion and a
diffuse interstitial pattern. A tube inserted in the right side of
the chest drained 800 mL of milky fluid. A trial of thoracic
duct embolization failed, and the patient continued to have
300 to 500 mL of chylous drainage daily. She remained dys-
pneic and hypoxemic. In the setting of a chylous effusion,
increased interstitial markings, and airflow obstruction, the
attending surgeon considered a diagnosis of lymphangi-
oleiomyomatosis. A high-resolution CT scan showed diffuse
cystic disease in both lung fields consistent with lymphangi-
oleiomyomatosis (Fig 1). Talc pleurodesis was performed
successfully. The estrogen supplement that she had been
receiving was discontinued and progesterone therapy was ini-
tiated. After 1 year’s follow-up, the patient has stable lung
function and no recurrence of the chylothorax.
Discussion. Pulmonary lymphangioleiomyomatosis is a
rare, idiopathic disease that most often affects women of
reproductive age. The average age at presentation is 33
years.1 Postmenopausal presentation, as in this case, is rare
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Fig 1. High-resolution CT scan showing diffuse cystic disease in both lung fields consistent with lymphangio-
leiomyomatosis.
and is usually reported in association with exogenous estro-
gen administration.2 Dyspnea, occurring in more than 90% of
patients, and pneumothorax, reported in more than 80% of
patients, are the most common clinical manifestations.3
Chylothorax is uncommon at presentation (0%-7%)1-3 but
will develop in 28% at some time in the course of the dis-
ease.3 Other symptoms include chest pain, cough, and
hemoptysis.3 Extrapulmonary manifestations may include
chylous ascites, abdominal or pelvic adenopathy or masses,
and renal angiomyolipomas.2
Smooth muscle proliferation within the airways, lymphat-
ics, and blood vessels is responsible for the various clinical
presentations of lymphangioleiomyomatosis.2,3 Lymphatic
obstruction may produce chylothorax or chyloperitoneum.
Involvement of blood vessels may result in interstitial bleed-
ing and hemosiderosis. Smooth muscle proliferation in the
airways leads to the development of airflow obstruction, dif-
fuse cystic changes, and frequently pneumothorax.
Pulmonary function testing reveals airflow obstruction
with normal or increased lung volumes and a diffusion
impairment.4 Plain chest radiographs usually show abnormal-
ities. The most common findings are a reticular interstitial
pattern, cysts or bullae, pneumothorax, or pleural effusion.4,5
High-resolution CT scans demonstrate a distinctive pattern
with discrete thin-walled cysts 3 to 40 mm in diameter, uni-
formly distributed throughout the parenchyma.5
In the setting of cystic changes and airflow obstruction, the
differential diagnosis includes eosinophilic granuloma and
emphysema. If additional findings such as chylous pleural
effusion, chylous ascites, or renal angiomyolipomas are pre-
sent, the CT scan may be considered diagnostic. However,
some patients with findings limited to the lung parenchyma
may require biopsy. Pathologic findings include diffuse cys-
tic changes and the proliferation of atypical smooth muscle
cells involving the air spaces, bronchioles, pleura, vascula-
ture, and lymphatics.2
These changes may be difficult to detect when tissue is
obtained by transbronchial rather than surgical biopsy.
Immunohistochemical staining with HMB-45, a monoclonal
antibody that binds to lymphangioleiomyomatosis cells, may
increase the diagnostic yield in this setting.4
The natural history of the disease is that of progressive
deterioration of pulmonary function. In two recent case
series, survival 8.5 years after the onset of symptoms ranged
from 38% to 78%.1,3 The administration of medroxyproges-
terone has been associated with improvement or stabilization
of the clinical course of the disease.3
Lung transplantation is an additional therapeutic option for
patients with advanced disease.
Given the rarity of lymphangioleiomyomatosis and the
observation that clinical symptoms may predate radiographic
findings, delays in diagnosis as in our case are common. The
clinical sequelae of lymphangioleiomyomatosis often require
intervention by thoracic surgeons. Familiarity with this rare
disease is therefore essential to assure prompt diagnosis and
optimum management.
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